CL2020002246A1 - Expresión de proteína de superficie a neumocócica (pspa) - Google Patents

Expresión de proteína de superficie a neumocócica (pspa)

Info

Publication number
CL2020002246A1
CL2020002246A1 CL2020002246A CL2020002246A CL2020002246A1 CL 2020002246 A1 CL2020002246 A1 CL 2020002246A1 CL 2020002246 A CL2020002246 A CL 2020002246A CL 2020002246 A CL2020002246 A CL 2020002246A CL 2020002246 A1 CL2020002246 A1 CL 2020002246A1
Authority
CL
Chile
Prior art keywords
pspa
surface protein
pneumococcal surface
protein expression
expression
Prior art date
Application number
CL2020002246A
Other languages
English (en)
Inventor
Rajan Sriraman
Ramesh Venkat Matur
Narender Dev Mantena
Mahima Datla
Swetha Kamireddy
Original Assignee
Biological E Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biological E Ltd filed Critical Biological E Ltd
Publication of CL2020002246A1 publication Critical patent/CL2020002246A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a la expresión de proteína de superficie A neumocócica (PspA). La invención representa un avance en el campo de ingeniería genética y tecnología de vacunas. La invención describe vectores de expresión y células hospederas recombinantes para la expresión del péptido PspA truncado. La invención también describe composiciones de vacuna que comprenden los péptidos truncados como proteína portadora.
CL2020002246A 2018-03-01 2020-08-31 Expresión de proteína de superficie a neumocócica (pspa) CL2020002246A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201841007814 2018-03-01

Publications (1)

Publication Number Publication Date
CL2020002246A1 true CL2020002246A1 (es) 2021-01-15

Family

ID=66440079

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002246A CL2020002246A1 (es) 2018-03-01 2020-08-31 Expresión de proteína de superficie a neumocócica (pspa)

Country Status (17)

Country Link
US (2) US11725029B2 (es)
EP (1) EP3758746A1 (es)
JP (2) JP7334176B2 (es)
KR (1) KR20200129121A (es)
CN (1) CN112118865A (es)
AU (1) AU2019226487A1 (es)
BR (1) BR112020017431A2 (es)
CA (1) CA3091583A1 (es)
CL (1) CL2020002246A1 (es)
CU (1) CU20200064A7 (es)
EA (1) EA202092065A1 (es)
IL (1) IL277023A (es)
MX (1) MX2020009049A (es)
PH (1) PH12020551357A1 (es)
SG (1) SG11202008124XA (es)
WO (1) WO2019167008A1 (es)
ZA (1) ZA202005414B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
WO2023039223A1 (en) 2021-09-09 2023-03-16 Affinivax, Inc. Multivalent pneumococcal vaccines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476929A (en) * 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
ES2444785T3 (es) 2004-09-09 2014-02-26 Research Institute Of Innovative Technology For The Earth Fragmento de ADN que tiene función promotora
CN105483067A (zh) 2008-06-25 2016-04-13 瓦克星治疗有限责任公司 可调型基因自杀机制组合物和方法
WO2010141312A2 (en) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
CN107674118A (zh) 2016-08-02 2018-02-09 中国食品药品检定研究院 重组蛋白PspA1、PspA2和PspA3以及包含其的多糖结合疫苗

Also Published As

Publication number Publication date
CA3091583A1 (en) 2019-09-06
MX2020009049A (es) 2020-10-12
AU2019226487A1 (en) 2020-09-10
WO2019167008A1 (en) 2019-09-06
EP3758746A1 (en) 2021-01-06
JP7334176B2 (ja) 2023-08-28
IL277023A (en) 2020-10-29
ZA202005414B (en) 2022-02-23
JP2023154063A (ja) 2023-10-18
US20210009641A1 (en) 2021-01-14
PH12020551357A1 (en) 2021-08-23
CU20200064A7 (es) 2021-04-07
BR112020017431A2 (pt) 2021-01-19
EA202092065A1 (ru) 2020-11-19
US11725029B2 (en) 2023-08-15
CN112118865A (zh) 2020-12-22
SG11202008124XA (en) 2020-09-29
JP2021516050A (ja) 2021-07-01
KR20200129121A (ko) 2020-11-17
US20230322871A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
CL2018000124A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer
PE20180505A1 (es) Peptidos y combinacion de peptidos y andamiajes novedosos para su uso en inmunoterapia contra carcinoma de celulas renales (rcc) y otros canceres
BR112017014560A2 (pt) profármacos de cnp
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
PE20181275A1 (es) Ensamble de polipeptido quimerico y metodos para hacer y usar el mismo
PE20181923A1 (es) Neoantigenos y metodos de su uso
CO7051009A2 (es) Composiciones del factor viii y métodos para hacerlas y usarlas
PE20181156A1 (es) Genes de ataxia de friedreich modificados y vectores para terapia genica
BR112017017867A2 (pt) métodos e composições para tratamento de doenças oculares genéticas
CO2018009120A2 (es) Genes del factor viii optimizados
BR112018006995A2 (pt) receptores anti-cd30 de antígeno quimérico
UY37970A (es) Plataforma de presentación, productos y métodos con endosporas basadas en paenibacillus
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
CL2020002246A1 (es) Expresión de proteína de superficie a neumocócica (pspa)
PE20160244A1 (es) Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos
UY37456A (es) Inmunoglobulinas y sus usos
UY35397A (es) INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
BR112017020308A2 (pt) udp-glicosiltransferases
ECSP17075380A (es) Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos
CL2018000164A1 (es) Vector recombinante del virus orf.
CL2021001251A1 (es) Plataformas, productos y métodos para la expresión en endosporas
CO2018001339A2 (es) Sistema vector de adenovirus aviar 9 (fadv-9) y métodos asociados
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2
CL2015002359A1 (es) Manipulación de autoincompatibilidad de plantas
CL2020001846A1 (es) Anticuerpos pac1 y sus usos